PSA inhibitors (Lilly)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePSA inhibitors (Lilly)
Drug Alias Nameprostate cancer therapy (Lilly)
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic NeoplasmsBreast NeoplasmsOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLilly Research Centre LtdUniversity Of Oxford
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsBreast NeoplasmsOsteosarcoma

Other Information

ATC CodeN/A
Related LinksN/A